225 related articles for article (PubMed ID: 33455838)
1. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives].
Prevel R; Roubaud-Baudron C; Tellier E; Le Besnerais M; Kaplanski G; Veyradier A; Benhamou Y; Coppo P;
Rev Med Interne; 2021 Mar; 42(3):202-209. PubMed ID: 33455838
[TBL] [Abstract][Full Text] [Related]
2. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
3. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity.
Tellier E; Widemann A; Cauchois R; Faccini J; Lagarde M; Brun M; Robert P; Robert S; Bachelier R; Poullin P; Roose E; Vanhoorelbeke K; Coppo P; Dignat-George F; Kaplanski G
Haematologica; 2023 Apr; 108(4):1127-1140. PubMed ID: 36453103
[TBL] [Abstract][Full Text] [Related]
5. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gómez-Seguí I; Francés Aracil E; Mingot-Castellano ME; Vara Pampliega M; Goterris Viciedo R; García Candel F; Pascual Izquierdo C; Del Río Garma J; Guerra Domínguez L; Vicuña Andrés I; Garcia-Arroba Peinado J; Zalba Marcos S; Vidan Estévez JM; González Arias E; Campuzano Saavedra V; García Gala JM; Ortega Sanchez S; Martínez Nieto J; Pardo Gambarte L; Solé Rodríguez M; Fernández-Docampo M; Avila Idrovo LF; Hernández L; Cid J; de la Rubia Comos J;
Br J Haematol; 2023 Dec; 203(5):860-871. PubMed ID: 37723363
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
[TBL] [Abstract][Full Text] [Related]
7. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
Sui J; Zheng L; Zheng XL
Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Mariotte E; Azoulay E; Galicier L; Rondeau E; Zouiti F; Boisseau P; Poullin P; de Maistre E; Provôt F; Delmas Y; Perez P; Benhamou Y; Stepanian A; Coppo P; Veyradier A;
Lancet Haematol; 2016 May; 3(5):e237-45. PubMed ID: 27132698
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
Poullin P
Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
[TBL] [Abstract][Full Text] [Related]
10. The standard of care for immune thrombotic thrombocytopenic purpura today.
Zheng XL
J Thromb Haemost; 2021 Aug; 19(8):1864-1871. PubMed ID: 34060225
[TBL] [Abstract][Full Text] [Related]
11. Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.
Brown J; Potugari B; Mazepa MA; Kohli R; Moliterno AR; Brodsky RA; Vaught JA; Burwick R; Chaturvedi S
Ann Hematol; 2022 Oct; 101(10):2159-2167. PubMed ID: 35932324
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age.
Rottenstreich A; Dor S; Keren-Politansky A; Sarig G; Nadir Y; Ellis M; Spectre G; Kirgner I; Pikovsky O; Arad A; Dann EJ; Kalish Y
J Thromb Thrombolysis; 2021 Jan; 51(1):187-193. PubMed ID: 32388825
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the diagnosis of thrombotic thrombocytopenic purpura.
Siniard RC; Gangaraju R; May JE; Marques MB
Expert Rev Hematol; 2023; 16(11):861-869. PubMed ID: 37767808
[TBL] [Abstract][Full Text] [Related]
14. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
[TBL] [Abstract][Full Text] [Related]
15. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
[TBL] [Abstract][Full Text] [Related]
16. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
[TBL] [Abstract][Full Text] [Related]
17. Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults.
Blennerhassett R; Curnow J; Pasalic L
Semin Thromb Hemost; 2020 Apr; 46(3):289-301. PubMed ID: 32259874
[TBL] [Abstract][Full Text] [Related]
18. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
19. Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.
Sakai K; Miyadera H; Kubo M; Nakajima F; Matsumoto M
J Thromb Haemost; 2023 Mar; 21(3):616-628. PubMed ID: 36696200
[TBL] [Abstract][Full Text] [Related]
20. Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
De Waele L; Curie A; Kangro K; Tellier E; Kaplanski G; Männik A; Tersteeg C; Joly BS; Coppo P; Veyradier A; De Meyer SF; Roose E; Vanhoorelbeke K
Blood Adv; 2021 Nov; 5(21):4480-4484. PubMed ID: 34559219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
